COMPASS Pathways plc

COMPASS did not report revenue or EPS on the call. The company emphasized clinical and regulatory progress instead: highly statistically significant positive Phase III primary endpoint readouts in both studies, 6-month durability from both trials, and safety/tolerability that management described as generally well tolerated and safe. Cash on hand was $433 million as of June 30, which management said carries it well through launch and into 2028. Forward-looking items: the company continues to expect to complete the NDA filing in the fourth quarter, anticipates launch in the first half of 2027, and said it is still subject to a fluid schedule tied to National Priority Review Voucher timing, FDA/DEA rescheduling, and state rescheduling.

Kabir Nath framed the quarter as a major de-risking moment, saying the company now has highly statistically significant Phase III data plus 6-month durability and believes COMP360’s clinical and regulatory profile is largely de-risked. He stressed disciplined execution on the rolling NDA submission, saying the team is responding quickly to FDA questions and pushing for a first-pass approval. His tone was confident but focused on process, repeatedly returning to filing completion, regulatory readiness, and launch preparation.

The CFO, Teri Loxam, did not give a formal financial review on the call, but management reiterated that COMPASS had $433 million of cash on hand as of June 30. Kabir said that balance sheet strength should carry the company well through launch and into 2028. No revenue, EPS, margin, burn, or detailed capital allocation figures were provided on the call.

Most analyst questions centered on FDA guidance for psychedelics, DEA rescheduling timing, REMS, launch reimbursement, training at sites, and whether COMPASS would broaden beyond TRD. Management said the new FDA psychedelic guidance should not affect the current regulatory process because the Phase III design was already aligned with the agency, and that the rolling review is progressing normally. On rescheduling, Lori Englebert said the company is accelerating its 8-factor analysis and believes the DEA typically acts within 90 days, though timing remains fluid. She also said launch prep is focused on payer engagement, field reimbursement support, REMS training after approval, and using the existing 8,000-plus interventional psychiatry sites for rollout.